Reports Q4 revenue $26.3M, consensus $24.34M. “Our outstanding fourth quarter and full year 2023 net revenue of $26.3 million and $80.8 million, respectively, mark major achievements for Alimera and are a testament to the realized vision and strong execution of our entire team in only our second full quarter marketing both ILUVIEN and YUTIQ,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “We are proud to have achieved positive Adjusted EBITDA during the fourth quarter of 2023, while maintaining a consistent net loss compared to the fourth quarter of 2022, despite facing greater interest and amortization expenses following the YUTIQ acquisition.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALIM:
- Alimera Sciences (ALIM) Q4 Earnings Cheat Sheet
- Alimera Sciences Launches 2024 Equity Inducement Plan
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
- Alimera announces NICE issued Final Draft Guidance on ILUVIEN
